← Ablatotech Vitals
Oncology EvidenceDigest

Role of Patient-Reported Outcomes in Guiding Treatment Decisions in Oncology

Oncology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 3, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Patient-reported outcomes (PROs) are increasingly recognized as valuable tools to guide treatment decisions in oncology by capturing patients’ symptom burden, functional status, and quality of life. Incorporating PROs into clinical care supports personalized therapy adjustments, enhances patient-clinician communication, and may improve clinical outcomes. While evidence is growing, implementation challenges and variability in PRO measures remain. Continued integration of PROs, especially in complex cancers such as metastatic breast and advanced prostate cancer, holds promise for more patient-centered oncology care.

Clinical bottom line

Patient-reported outcomes (PROs) are increasingly recognized as valuable tools to guide treatment decisions in oncology by capturing patients’ symptom burden, functional status, and quality of life. Incorporating PROs into clinical care supports personalized therapy adjustments, enhances patient-clinician communication, and may improve clinical outcomes. While evidence is growing, implementation challenges and variability in PRO measures remain. Continued integration of PROs, especially in complex cancers such as metastatic breast and advanced prostate cancer, holds promise for more patient-centered oncology care.

What the evidence shows

Burla et al. (2025) explored patient perspectives on PRO-based reports combined with coaching sessions, finding that patients valued the opportunity to communicate symptoms and treatment impact more effectively. This approach facilitated shared decision-making and increased patient engagement.

Wang et al. (2025) reviewed the role of PROs in geriatric oncology, emphasizing their importance in assessing treatment tolerance and guiding therapy modifications in older adults, a population often underrepresented in clinical trials.

Andre et al. (2022) updated ASCO guidelines on biomarkers in early-stage breast cancer, highlighting that PROs complement molecular data by providing real-world insights into treatment tolerability and patient preferences, which can influence adjuvant therapy choices.

Singareeka Raghavendra et al. (2026) discussed personalization of therapies in hormone receptor-positive/HER2-negative metastatic breast cancer, noting that PROs are integral to monitoring symptom trajectories and optimizing sequential treatment strategies.

Gillessen et al. (2023) reported consensus recommendations from the Advanced Prostate Cancer Consensus Conference, underscoring the role of PROs in managing metastatic and castration-resistant prostate cancer to balance efficacy and quality of life.

Roberts et al. (year not specified) described practical considerations for implementing PROs in medical oncology settings, including workflow integration, electronic health record compatibility, and clinician training to maximize utility.

Patient perspectives on PRO measurement highlight the need for clear communication about the purpose of PROs and ensuring that data collected meaningfully informs care (Oncology Nursing Forum, 2026).

Caveats and uncertainty

Heterogeneity in PRO instruments and lack of standardization complicate comparisons across studies and clinical settings. Some measures may not capture all relevant domains for specific cancers or treatments.

Implementation barriers include clinician time constraints, data overload, and limited integration with clinical workflows. Patient factors such as literacy and technology access can affect PRO completion and accuracy.

Evidence linking PRO-guided treatment adjustments to improved survival or long-term outcomes remains limited, with most data focusing on symptom control and quality of life.

How this may change practice

Routine collection of PROs can enhance individualized treatment planning by identifying symptoms early and informing dose modifications or supportive care interventions.

Oncology teams should prioritize selecting validated, disease-specific PRO tools and develop workflows that integrate PRO data into clinical decision-making without disrupting care delivery.

Training clinicians to interpret and act on PRO data is critical to realize benefits. Engaging patients in understanding the role of PROs may improve adherence and data quality.

As evidence matures, PROs may become standard components of clinical trials and real-world practice, supporting value-based oncology care that aligns with patient goals.


References

  1. Andre F, et al. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. J Clin Oncol 2022;40(16):1846-1867. DOI:10.1200/JCO.22.00069
  2. Singareeka Raghavendra A, et al. Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer. CA Cancer J Clin 2026;76(1):45-67. DOI:10.3322/caac.70055
  3. Burla M, et al. Patient perspectives on a PRO-based report and coaching session to inform treatment decisions. Adv Patient-Reported Outcomes 2025;10:100286. DOI:10.1016/j.apro.2025.100286
  4. Wang XS, et al. Role of patient-reported outcomes in geriatric oncology research and patient care. Holistic Integr Oncol 2025;3(2):45-58. DOI:10.1007/s44178-025-00198-w
  5. Gillessen S, et al. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer 2023;177:1-15. DOI:10.1016/j.ejca.2023.02.018
  6. Roberts N, et al. Implementing patient-reported outcomes in a medical oncology setting. [Thesis]. DOI:10.5204/thesis.eprints.208324
  7. Oncology Nursing Forum. Patient Perspectives on Measuring Patient-Reported Outcomes in Oncology. Oncol Nurs Forum 2026;53(2):e265-e333

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team